Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models

•An in vivo Hollow Fiber Assay for immuno-oncology drug testing.•Time and cost-efficient in vivo evaluation on cancer-and immune cells of human origin.•Co-cultures grown in semipermeable hollow fibers implanted in mice.•Monitoring of immune-cell mediated cancer cell killing in multiple fibers per mo...

Full description

Saved in:
Bibliographic Details
Published in:SLAS technology 2024-12, Vol.29 (6), p.100232, Article 100232
Main Authors: Selvin, Tove, Berglund, Malin, Åkerström, Anders, Zia, Marco, Rudfeldt, Jakob, Jarvius, Malin, Larsson, Rolf, Andersson, Claes R, Fryknäs, Mårten
Format: Article
Language:English
Subjects:
Animals
Cell Line, Tumor
Coculture Techniques
Disease Models, Animal
Hollow fibers
Humans
Immuno-oncology
Immunotherapy - methods
Mice
Mouse models
Neoplasms - immunology
Pilot Projects
Preclinical modeling
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•An in vivo Hollow Fiber Assay for immuno-oncology drug testing.•Time and cost-efficient in vivo evaluation on cancer-and immune cells of human origin.•Co-cultures grown in semipermeable hollow fibers implanted in mice.•Monitoring of immune-cell mediated cancer cell killing in multiple fibers per mouse.•Potential to reduce and refine animal use in immuno-oncology research. To facilitate the translation of immunotherapies from bench to bedside, predictive preclinical models are essential. We developed the in vivo immuno-oncology Hollow Fiber Assay (HFA) to bridge the gap between simpler cell-based in vitro assays and more complex mouse models for immuno-oncology drug evaluation. The assay involves co-culturing human cancer cell lines or primary patient-derived cancer cells with human immune cells inside semipermeable hollow fibers. Implanted intraperitoneally in mice, the fibers captured treatment-induced immune cell-mediated cancer cell killing following treatments with aCD3 and/or IL-2, demonstrating the feasibility of the assay. Traditional models require lengthy observation periods to monitor tumor growth and treatment response. The immuno-oncology HFA enables a rapid initial in vivo evaluation of immunological agents on cancer and immune cells of human origin, addressing two of the 3Rs — reduction and refinement — in animal research.
ISSN:2472-6303
2472-6311
2472-6311
DOI:10.1016/j.slast.2024.100232